Hoffmann-La Roche

IMBrave | WO41535

NCT04102098

JCP071

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

Adjuvant

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Atezolizumab + Bevacizumab

Treatment Arms

o Experimental: Arm A (atezolizumab plus bevacizumab)

o No Intervention: Arm B (active surveillance)